Logo

Jeffery Luber

Oct 03, 2017

Atlas Genetics announced today that Jeffrey Luber has been appointed CEO and John Clarkson, current founding CEO, will become Executive Chairman. Mr. Luber joins the board with experience in the life sciences industry, including roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae. Prior to this, Luber was CEO of Exact Sciences, where he executed its turnaround and strategic transaction with Genzyme. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.